Cytel Names Joshua Schultz as Chief Executive Officer

Cytel Sets Course for Further Growth with New CEO Appointment

Cambridge, MA, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cytel Inc., a global provider of advanced analytical solutions to the pharmaceutical, biotechnology, and medical device industries, today announced the appointment of Joshua Schultz as Chief Executive Officer (CEO) effective January 7th, 2019. He succeeds Joseph Avellone, who acted as Cytel’s interim CEO from March 2018 and will continue to serve on the company’s Board of Directors.

Mr. Schultz is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an Officer of the company and Senior Vice President for its Access business unit.  

Speaking on behalf of the Board of Directors, Cyrus Mehta, Co-Founder of Cytel said, “As a recognized pioneer in advanced analytics, Cytel is in a very strong position today. We are delighted to have found a high-caliber leader in Joshua Schultz to take us forward into the next chapter of growth for the company. Along with an exceptional commercial track record, Joshua shares the commitment to technological innovation, talent development, and cutting edge research that shaped Cytel's history. Therefore, we are confident that under his leadership we will further enhance the value we deliver to our customers, employees, and the life science industry as a whole."

Mr. Schultz has built and led groups for services spanning the development lifecycle, including study-start up, late phase trials, and market access. His achievements include the development of novel approaches to building high-value strategic partnerships with life science companies and creating innovative operational models that leverage real-world data and related technologies.

“I am honored and excited to join Cytel as we enter a new and exceptionally promising era for the life science industry. The largely unrealized potential for advanced analytics to improve the speed and effectiveness of clinical research is immense.  In addition, there is tremendous opportunity to apply existing and novel analytic methodologies to the emerging space of real-world data to create even further value,” Schultz said, reflecting on his appointment. “Cytel has enjoyed unprecedented growth underpinned by quality service and an earned reputation for scientific excellence within the biopharma and medical device community.  With unrivaled expertise in biostatistics and analytical solutions, I believe that we are uniquely placed to unlock the value of increasingly complex data and accelerate the development of promising new medicines. I am looking forward to working with our talented team to realize this strategic vision.”

Mr. Schultz holds a B.S.E. in Finance from the Wharton School of Business, a B.A. in International Relations from the University of Pennsylvania, and a Masters of Philosophy in International Relations from the University of Cambridge, UK.  He will be based at Cytel’s global headquarters in Cambridge, Massachusetts.

About Cytel

As a pioneer in evidence generation, with deep expertise in advanced analytical solutions, Cytel is uniquely equipped to unlock the value from increasingly complex data. Life sciences companies count on Cytel to deliver exceptional insight, minimize trial risk, and accelerate the development of promising new medicines that improve human life. Cytel provides data-focused clinical research services and software solutions for the design and analysis of clinical trials, including industry standards East®, StatXact®, and LogXact®. With operations across North America, Europe, and India, Cytel employs 900 professionals, with strong talent in biostatistics, programming, data science, and data management. For more information about Cytel, visit



Joshua Schultz, CEO of Cytel

Contact Data